Related Experiment Video

Updated: Apr 17, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.9K

Drug target optimization in chronic myeloid leukemia using innovative computational platform

Ryan Chuang1, Benjamin A Hall2, David Benque3

  • 1Department of Applied Mathematics and Theoretical Physics, University of Cambridge, Cambridge CB3 0WA, UK.

Scientific Reports
|February 4, 2015
PubMed

Insights

This study introduces BioModelAnalyzer (BMA), a computational tool to model Chronic Myeloid Leukemia (CML) networks. BMA identifies novel combinatorial drug targets and sensitivities, addressing drug resistance in CML treatment.

Area of Science:

  • Oncology
  • Computational Biology
  • Genetics

Background:

  • Chronic Myeloid Leukemia (CML) treatment faces challenges due to drug resistance.
  • Targeted therapies like tyrosine kinase inhibitors are effective but can be limited by resistance mechanisms.
  • Understanding the complex genetic network is crucial for optimizing CML drug development.

Purpose of the Study:

  • To develop a comprehensive computational model of the CML genetic network.
  • To utilize the model for identifying novel combinatorial therapeutic targets.
  • To explore drug resistance mechanisms and uncover new therapeutic sensitivities.

Main Methods:

  • Developed a CML network-model using BioModelAnalyzer (BMA), integrating data from 160 publications.
  • The model comprises 54 nodes and 104 interactions, representing dynamic cellular processes.
  • Systematically tested drug target combinations within the genetic network.

Main Results:

  • The executable model facilitated the analysis of multi-pathway interactions and cellular outcomes.
  • Identified potential new combinatorial therapeutic targets for CML.
  • Highlighted previously unrecognized sensitivities to Interleukin-3.

Conclusions:

  • BioModelAnalyzer (BMA) provides a powerful platform for dissecting CML complexity.
  • The model aids in predicting therapeutic responses and overcoming drug resistance.
  • This approach enables the systematic exploration of targeted therapies in CML.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
98